Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Paratek Pharmaceuticals' Shares Gain Following FDA Fast Track Designation For Nontuberculous Mycobacterial (NTM) Drug

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead drug NUZYRA (omadacycline) for the treatment of pulmonary Nontuberculous Mycobacterial (NTM) disease caused by both Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB).

NUZYRA is being investigated in the phase 2b clinical study, currently enrolling subjects for the safety and efficacy in patients with NTM pulmonary disease caused by MAB.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.